General
Preferred name
IBUDILAST
Synonyms
AV-411 ()
KC-404 ()
MN-166 ()
Ibudilast (KC-404) ()
KC-404, AV411, MN166 ()
AV411 ()
KETAS ()
Ibudilast-d7 ()
P&D ID
PD002711
CAS
50847-11-5
050847-11-5
2713301-45-0
Tags
available
drug
Approved by
PMDA
First approval
1989
Drug indication
Alcohol dependence
Methamphetamine dependence
Multiple sclerosis
Airway obstruction
Amyotrophic lateral sclerosis
Opioid dependence
Castleman's disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Ibudilast is a phosphodiesterase (PDE) inhibitor antiinflammatory drug. See the Biological activity tab for affinity data across a range of PDE isozymes. (GtoPdb)
DESCRIPTION Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia[1].
PRICE 29
DESCRIPTION Ibudilast has mechanisms that include anti-inflammatory effects, such as phosphodiesterase inhibition, and neuroprotective effects, such as inhibition of nitric oxide synthesis and reduction in reactive oxygen species. (Enamine Bioactive Compounds)
DESCRIPTION PDE inhibitor (non-selective) (Tocriscreen Plus)
DESCRIPTION Phosphodiesterase IV (PDE IV) inhibitor (LOPAC library)
DESCRIPTION PDE inhibitor (non-selective) (Tocriscreen Total)
DESCRIPTION Cyclooxygenase inhibitor; may be selective for COX-3 (Tocris Bioactive Compound Library)
DESCRIPTION Ibudilast (MN-166)(KC-404;AV-411;MN-166) is a relatively nonselective phosphodiesterase inhibitor. It is approved for use as an anti-inflammatory in Japan. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
35
AdooQ Bioactive Compound Library
A11019
Cayman Chemical Bioactives
14832
28876
ChEMBL Approved Drugs
CHEMBL19449
ChEMBL Drugs
CHEMBL19449
Concise Guide to Pharmacology 2017/18
7399
Concise Guide to Pharmacology 2019/20
7399
Concise Guide to Pharmacology 2021/22
7399
Concise Guide to Pharmacology 2023/24
7399
Concise Guide to Pharmacology 2025/26
7399
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB05266
DrugCentral
1406
DrugCentral Approved Drugs
1406
DrugMAP
DM4LSPN
DrugMAP Approved Drugs
DM4LSPN
DrugMatrix
Enamine Bioactive Compounds
EBC-47047
EU-OPENSCREEN Bioactive Compound Library
EOS100007
EUbOPEN Chemogenomics Library
EUB0002598
Guide to Pharmacology
7399
JUMP-Target 1 Compound Set
3671
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL19449
MedChem Express Bioactive Compound Library
HY-B0763
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Ibudilast
TargetMol Bioactive Compound Library
T2137
Tocris Bioactive Compound Library
1694
Tocriscreen Plus
1694
Tocriscreen Total
ZINC Tool Compounds
ZINC000000004234
External IDs
80
Properties
(calculated by RDKit )
Molecular Weight
230.14
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
0
Rotatable Bonds
3
Ring Count
2
Aromatic Ring Count
2
cLogP
3.3
TPSA
34.37
Fraction CSP3
0.43
Chiral centers
0.0
Largest ring
6.0
QED
0.76
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Enzymes
Selectivity
PDE IV
Target
PDE
phosphodiesterase
IL1B, IL6, PDE3A, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A
PDE4D
Phosphodiesterase (PDE)
Primary Target
Phosphodiesterases
MOA
Inhibitor
TLR4 (LPS) Receptor Antagonists
Leukotriene CysLT1 (LTD4) Antagonists
Phosphodiesterase Inhibitors
Mediator Release Inhibitors
leukotriene receptor antagonist, phosphodiesterase inhibitor
Member status
virtual
Indication
asthma, stroke
Disease Area
pulmonary, neurology/psychiatry
Pathway
Metabolism
Metabolic Enzyme/Protease
Recommended Cell Concentration
1 uM
Source data